BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); chemokine CXC motif ligand 5 (CXCL5; ENA78)

January 21, 2016 8:00 AM UTC

Mouse and cell culture studies suggest CXCR2 inhibitors could help treat invasive prostate cancer. In a mouse model of highly invasive prostate cancer, tumor levels of CXCL5 and CXCR2-expressing myeloid-derived suppressor cells (MDSCs) were increased compared with levels in a mouse model of less invasive prostate cancer. In prostate cancer cells from the highly invasive model, CXCR2 knockdown decreased cell migration, and pharmacological inhibition of CXCR2 with a tool compound decreased tumor growth and increased survival, compared with vehicle. Next steps include testing depletion of regulatory immune cells on the effect of immune checkpoint blockers in mouse models.

AstraZeneca plc has AZD5069, a CXCR2 antagonist, in Phase II testing to treat chronic obstructive pulmonary disease (COPD)...